Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2012.544 | Arterial stiffness indices in mothers of Hyperglycaemia and Adverse Pregnancy outcome (HAPO) study and their children offspring – a HAPO follow-up study | Prof. MA Ronald Ching Wan |
| 2013.500 | Gestational age specific thyroid function reference range in Hong Kong | Prof. MA Ronald Ching Wan |
| 2011.407 | The cardiometabolic risk amongst women with a prior history of hypertensive disorder | Prof. MA Ronald Ching Wan |
| 2015.641 | The impact of gestational diabetes mellitus and vitamin D deficiency during pregnancy on children’s cardiometabolic risk and methylation | Prof. MA Ronald Ching Wan |
| 2017.291 | Validation of a novel assay for measurements of biologically active Angiotensin peptides(AngP) by Liquid chromatography Mass Spectrometry(LCMS)for the screening and diagnosis of Conn’s syndrome in hypertensive patients |
Prof. MA Ronald Ching Wan 馬青雲 |
| 2015.547 | A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care |
Prof. MA Ronald Ching Wan 馬青雲 |
| 2017.268 | A randomized clinical trial using a postnatal lifestyle modification program to improve diet, adiposity and metabolic outcome in mothers with gestational diabetes and their offspring | Prof. MA Ronald Ching Wan |
| 2016.442 | RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS CARDIOVASCULAR OUTCOMES FOLLOWING TREATMENT WITH ERTUGLIFLOZIN (MK-8835/PF-04971729) IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED VASCULAR DISEASE, THE VERTIS CV STUDY |
Prof. MA Ronald Ching Wan 馬青雲 |
| 2015.473 | Identification of genetic loci for birthweight and cardiometabolic traits in childhood |
Prof. MA Ronald 馬青雲 |
| 2013.432 | Identification of epigenetic markers in offspring exposed to maternal hyperglycaemia | Prof. MA Ronald |
| 2016.328 | Epigenetic markers of type 2 diabetes and diabetic complications |
Prof. MA Ronald 馬青雲 |
| 2015.040 | Progression of glucose intolerance, cardiometabolic risk factors and subclinical atherosclerosis in Chinese women with Polycystic Ovary Syndrome | Prof. MA Ronald |
| 2015.316 | Maternal exposure to Perfluorooctane sulfonate (PFOS) and the risk of childhood obesity and metabolic abnormalities in the offspring- analysis of a longitudinal birth cohort |
Prof. MA Ronald 馬青雲 |
| 2016.103 | Unraveling the link between maternal hyperglycaemia and childhood obesity: Genome-wide methylation analysis in a prospective cohort of untreated gestational diabetes |
Prof. MA Ronald 馬青雲 |
| 2018.357 | Comprehensive evaluation and mechanism investigation of the PAX4 gene R192H variant on diabetes, diabetes-related traits and diabetic complications |
Prof. MA Ronald 馬青雲 |
| 2022.475 | Translating multi-omic discoveries to transform diabetes care and reduce diabetic complications Substudy 1: A randomized controlled trial to evaluate the clinical utility of communicating polygenic risk scores in diabetes | Prof. MA Ronald |
| 2011.047 | Identification of genetic variants assocaited with atrial fibrillation and its effect in subjects with diabetes | Prof Ma Ronald |
| 2008.519 | The role of neurohormonal dysregulation in the transgenerational effects of maternal diabetes | Prof Ma Ronald |
| 2013.447 | Developing a Metagenomic Next-Generation Sequencing Software Platform for Discovering Biomarkers with Application to Obesity and Type 2 Diabetes | Prof. MA Ronald |
| 2013.304 | An integrated trans-omics approach to diabetic cardio-renal complications: from novel discoveries to personalized medicine Substudy 2: The Hong Kong Diabetes Biobank | Prof. MA Ronald |
| 2013.187 | An integrated trans-omics approach to diabetic cardio-renal complications: from novel discoveries to personalized medicine | Prof. MA Ronald |
| 2013.042 | Identification of clinical and genetic predictors of hyperglycaemia and impaired beta-cell function in Chinese children- an analysis using mother-offspring pairs | Prof. MA Ronald |
| 2011.118 | Genetic determinants of obesity and cardiometabolic traits in Chinese adolescents | Professor Ma Ronald |
| 2013.251 | An integrated trans-omics approach to diabetic cardio-renal complications: from novel discoveries to personalized medicine - Substudy 1: Transcriptome analysis of diabetic kidney disease | Prof. MA Ronald |
| 2011.354 | Identification of epigenetic markers associated with maternal diabetes and obesity | Prof. MA Ronald |
| 2011.302 | Identificatin and large-scale replication of genetic predictors of diabetic kidney disease and diabetic retinopathy in the Chinese population | Prof Ma Ronald |
| 2008.518 | Progression of cardio-metabolic risk factors in Chinese women with Polycystic Ovary Syndrome | Prof Ma Ronald |
| 2015.458 | The effect of imagery and rumination on depression: a mediation and intervention study |
Ms. MA Olivia 馬婉婷 |
| 2015.241 | A Transdiagnostic Anger Management Program for Adult Psychiatric Inpatient |
Ms. MA Olivia 馬婉婷 |
| 2022.043 | Effects of a structured Tai Chi program on improving physical activity level, exercise self-efficacy, and health outcomes among pregnant women: A randomised controlled trial |
Ms. MA Nan 马楠 |
| 2013.407 | Pharmacokinetic study of once-daily formulation of Tacrolimus (Advagraf_) in Chinese kidney transplant patients | Dr Ma King Wing, Terry |
| 2023.153 | Mitochondrial disease related mortality - evaluation of a large international cohort | Dr. MA Kam Hung |
| 2012.321 | An opinion Survey among frail elderly patients and their carers regarding their opinion about self-financed community care services | Dr MA HON MING |
| 2017.282 | Mindfulness-based cognitive therapy for community-dwelling adults with anxiety symptoms: An exploration of efficacy and cognitive mechanism |
Miss MA Duan Yang 馬端陽 |
| 2012.052 | An evaluation on the effectiveness, acceptability and pricing of annual complication assessment for people with diabetes mellitus in the Hong Kong Community | Prof Ma Ching-wan, Ronald |
| 2010.466 | SAVOR Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus A Multicenter, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients with Type 2 Diabetes | Professor Ma Ching Wan Ronald |
| 2010.473 | An East Asian phase I, multicenter, open-label, dose-escalation study of oral LDE225 in patients with advanced solid tumors | Associate Prof. Ma Buig Yue Brigette |
| 2010.251 | Uncontrolled, open-label, non-randomized, phase 1 study to investigate the pharmacokinetics, safety, tolerability, and efficacy of BAY 73-4506 in Chinese patients with advanced, refractory solid tumors | Associate Professor Ma Brigette Buig-Yue |
| 2017.540 | A phase I/II study of safety and efficacy of ribociclib (LEE011) in combination with trametinib (TMT212) in patients with metastatic or advanced solid tumors |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2019.153 | A Phase I/Ib, open-label, multi-center study of NZV930 as a single agent and in combination with PDR001 and/or NIR178 in patients with advanced malignancies |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2020.054 | A phase I/Ib, open-label, multi-center, study of KAZ954 as a single agent and in combination with Spartalizumab, NZV930 and NIR178 in patients with advanced solid tumors |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2018.436 | A Phase Ib, multicenter, open-label dose escalation and expansion platform study of select immunotherapy combinations in adult patients with triple negative breast cancer |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2020.367 | A FIRST IN-HUMAN, PHASE 1/2 STUDY OF CFI-402411, HEMATOPOIETIC PROGENITOR KINASE-1 (HPK1) INHIBITOR, AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH ADVANCED SOLID MALIGNANCIES |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2019.327 | A Phase Ib, open-label, multi-center study to characterize the safety, tolerability, and preliminary efficacy of TNO155 in combination with spartalizumab or ribociclib in selected malignancies |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2020.591 | AN OPEN-LABEL, PHASE III STUDY OF PLATINUM-GEMCITABINE WITH OR WITHOUT NIVOLUMAB IN THE FIRST-LINE TREATMENT OF RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA |
Prof. MA Brigette Buig Yue 馬碧如 |
| 2019.002 | A phase I/Ib, open-label, multi-center, study of DKY709 as a single agent and in combination with PDR001 in patients with advanced solid tumors |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2020.168 | A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma |
Prof. MA Brigette Buig Yue 馬碧如 |
| 2019.684 | An open-label, multi-center rollover protocol for continued characterization of safety and tolerability for subjects who have participated in a Novartis-sponsored spartalizumab study as single agent or in combination with other study treatments |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2020.457 | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB PLUS TIRAGOLUMAB IN COMBINATION WITH PACLITAXEL AND CISPLATIN COMPARED WITH PACLITAXEL AND CISPLATIN AS FIRST-LINE TREATMENT IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED, UNRESECTABLE RECURRENT, OR METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA |
Prof. MA Brigette Buig Yue 馬碧如 教授 |
| 2019.342 | Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination with Pembrolizumab in Advanced Cancer |
Prof. MA Brigette Buig Yue 馬碧如教授 |
Page 98 of 262.